Eculizumab for bevacizumab induced thrombotic microangiopathy: A case report

Creative Commons License

İnözü M., Özlü S. G., Özyörük D., KİREMİTCİ S., Çakmakçı S., Avcı B., ...More

Pediatric Hematology Oncology Journal, vol.7, no.4, pp.169-172, 2022 (Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 7 Issue: 4
  • Publication Date: 2022
  • Doi Number: 10.1016/j.phoj.2022.08.006
  • Journal Name: Pediatric Hematology Oncology Journal
  • Journal Indexes: Scopus
  • Page Numbers: pp.169-172
  • Keywords: Bevacizumab, Eculizumab, Thrombotic microangiopathy
  • Ankara University Affiliated: Yes

Abstract

Bevacizumab is a monoclonal human antibody that is effective in the treatment of cancers in both adults and children due to inhibition of vascular endothelial growth factor. Throbotic microangiopathy (TMA) is well-known complication of bevacizumab. Herein, we report a case of desmoplastic small round cell tumor in a 17-year-old male presenting with TMA after bevacizumab treatment. Eculizumab was administered as second line agent for treatment of thrombotic microangiopathy and partial remission was achieved. With this case report we would like to emphasize the renal effects of bevacizumab and discuss the role of eculizumab in the treatment of bevacizumab related TMA.